Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Grazia Pennisi, Salvatore Petta, Daniela Cabibi, Quentin M. Anstee, Gian Paolo Caviglia, Olivier Govaere, Fabio M. Vecchio, Fabio M. Vecchio, Chiara Rosso, Antonio Grieco, Paolo Francione, Marco Y W Zaki, Antonio Liguori, Ramy Younes, Antonio Grieco, Angelo Armandi, Dina Tiniakos, Maria J Garcia Blanco, Luca Valenti, Elisabetta BugianesiAnna L. Fracanzani, Marco Maggioni, Luca Miele, Ezio David, Alastair Burt

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
Original languageEnglish
Pages (from-to)1289-1292
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume115
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease'. Together they form a unique fingerprint.

Cite this